After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Ionis Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Ionis Pharmaceuticals Inc is $13.28B. A total of 1.87 million shares were traded on the day, compared to an average of 2.85M shares.
In the most recent transaction, Joseph Wender bought 14,479 shares of IONS for 81.99 per share on Dec 01 ’25. In a previous transaction on Nov 25 ’25, KLEIN JOSEPH III sold 12,000 shares at 80.00 per share. IONS shares that Director owns now total 0.
Among the insiders who sold shares, Devers Shannon L. disposed of 16,777 shares on Nov 25 ’25 at a per-share price of $80.91. This resulted in the EVP, Chief Human Resources Ofc holding 17,494 shares of IONS after the transaction. In another insider transaction, Devers Shannon L. bought 42,322 shares at $80.91 per share on Nov 25 ’25.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, IONS has a high of $82.95 and a low of $23.95.
As of this writing, IONS has an earnings estimate of -$1.2 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.81 per share and a lower estimate of -$1.42. The company reported an EPS of -$0.43 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. IONS’s latest balance sheet shows that the firm has $2.11B in Cash & Short Term Investments as of fiscal 2021. There were $1.25B in debt and $240.55M in liabilities at the time. Its Book Value Per Share was $3.84, while its Total Shareholder’s Equity was $771.74M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Buy with a score of 4.39.
